Detalles de la búsqueda
1.
Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Eur Respir J
; 61(2)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36041751
2.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
N Engl J Med
; 380(26): 2518-2528, 2019 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31112379
3.
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Ann Rheum Dis
; 81(12): 1722-1729, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973804
4.
Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Rheumatology (Oxford)
; 60(4): 1915-1925, 2021 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33155024
5.
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
Mod Rheumatol
; 31(1): 141-150, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32243207
6.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Ann Rheum Dis
; 79(11): 1478-1484, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32759258
7.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply.
N Engl J Med
; 381(16): 1596-1597, 2019 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31618556
8.
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Clin Exp Rheumatol
; 35 Suppl 106(4): 75-81, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664834
9.
Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
Respir Res
; 16: 87, 2015 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26177937
10.
Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting ß2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.
Respir Res
; 16: 97, 2015 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-26283085
11.
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.
Pediatr Pulmonol
; 59(4): 1038-1046, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38289091
12.
Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.
J Allergy Clin Immunol
; 128(2): 308-14, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21636120
13.
An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP).
Sci Rep
; 12(1): 8708, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35610268
14.
A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Eur J Drug Metab Pharmacokinet
; 47(1): 81-89, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34664183
15.
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Arthritis Rheumatol
; 74(3): 518-526, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34514739
16.
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Respir Investig
; 59(2): 252-259, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33223487
17.
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Lancet Respir Med
; 9(1): 96-106, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33412120
18.
Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations.
BMJ Open
; 10(12): e039473, 2020 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33328257
19.
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.
J Scleroderma Relat Disord
; 4(3): 212-218, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35382502
Resultados
1 -
19
de 19
1
Próxima >
>>